undamentalytics Newsletter
Sign in

Rigel Pharmaceuticals Inc income statement

In fiscal 2025, Rigel Pharmaceuticals Inc reported revenue of $294m, up 64.1% on the year before, operating income of $125m (a 42.6% margin) and net income of $367m, or $19.48 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2044559109149120117179294277
Cost of revenue——011127192024
Gross profit——4458108148118110161275253
Research and development6346475360656025233344
Selling, general and administrative213870757792112106113116122
Operating income−70−80−73−69−29−12−56−202412587
Interest expense———01547876
Income before tax———−67−30−17−59−251812286
Income tax000——1—01−245−236
Net income−69−78−70−67−30−18−59−2517367322
Diluted EPS−$7.30−$6.20−$4.40−$4.00−$1.80−$1.10−$3.44−$1.44$0.99$19.48$16.45
Diluted shares (average)9m13m16m17m17m17m17m17m18m19m20m
EBITDA−69−79−72−68−28−11−55−192612890

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HROW vs RIGLEOLS vs RIGLACB vs RIGL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Rigel Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rigel Pharmaceuticals Inc.